Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling

Tregs with multifaceted functions suppress anti-tumor immunity by signaling surrounding cells. Tregs use the surface LTa1b2 to preferentially stimulate LTbR nonclassical NFkB signaling on both tumor and LECs to accelerate tumor growth and metastasis. Selectively targeting LTβR nonclassical NFkB pathways on both tumors and LECs cocultured with Tregs, inhibits tumor growth and migration in vitro. Leveraging in vivo Treg LTa1b2 interactions with LTβR on tumor and LECs, transfer of WT but not LTa-/- Tregs promotes B16F10 melanoma growth and tumor cell-derived chemokines in LTβR-/- mice; and increases SOX18 and FLRT2 in lymphatic vessels of LTbR-/-melanoma. Blocking the nonclassical pathways suppresses tumor growth and lymphatic metastasis by reducing chemokine production, restricting Treg and MDSC recruitment to tumors, and retaining intratumoral IFNg+ CD8 T cells. Our data reveals that Treg LTa1b2 promotes LTbR nonclassical NFkB signaling in tumor cells and LECs providing a rational strategy to prevent Treg promoted tumor growth and metastasis. Best regards 10 groups of total RNA sample from B16F10 melanoma with differential treatment. First 5 sets: WT B16F10 pretreated with classical LTbR-NFkB blocking peptide ciLT (20uM) for 30 min, wash and stimulated with anti-LTbR agonist Ab (3C8) for 1 hour, CRISPR-Cas9 IKKb KO B16F10 used as a control; 2nd 5 sets: WT B16F10 pretreat with nonclassical NFkB blocking peptide nciLT (20uM) for 30 min,wash then stimulated with 3C8 for 6 hours. CRISPR-Cas9 NIK KO used as a control.